FAP and lung cancer: Kakarla et al. [78] used an anti-FAP CAR specific for both murine and human FAP with a CD28 costimulatory domain against murine lung cancer models and saw a decrease in tumor growth that could be further enhanced by co-treatment with tumor-targeting cells.